CN1276777C - SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene - Google Patents
SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene Download PDFInfo
- Publication number
- CN1276777C CN1276777C CN 200410044285 CN200410044285A CN1276777C CN 1276777 C CN1276777 C CN 1276777C CN 200410044285 CN200410044285 CN 200410044285 CN 200410044285 A CN200410044285 A CN 200410044285A CN 1276777 C CN1276777 C CN 1276777C
- Authority
- CN
- China
- Prior art keywords
- sars
- gene
- vaccine
- preparation
- coronavirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000315672 SARS coronavirus Species 0.000 title claims abstract description 69
- 201000003176 severe acute respiratory syndrome Diseases 0.000 title claims abstract description 68
- 229960005486 vaccines Drugs 0.000 title claims abstract description 49
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 40
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000000969 carrier Substances 0.000 title abstract description 8
- 230000002950 deficient Effects 0.000 claims abstract description 16
- 238000000746 purification Methods 0.000 claims abstract description 7
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 210000002356 Skeleton Anatomy 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 241001135569 Human adenovirus 5 Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 12
- 230000003612 virological Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 210000001533 Respiratory Mucosa Anatomy 0.000 abstract description 5
- 102000004965 antibodies Human genes 0.000 abstract description 5
- 108090001123 antibodies Proteins 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 230000002163 immunogen Effects 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 230000001681 protective Effects 0.000 abstract description 3
- 230000000875 corresponding Effects 0.000 abstract description 2
- 201000009910 diseases by infectious agent Diseases 0.000 abstract description 2
- 238000010255 intramuscular injection Methods 0.000 abstract description 2
- 239000007927 intramuscular injection Substances 0.000 abstract description 2
- 229920001184 polypeptide Polymers 0.000 abstract description 2
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000010790 dilution Methods 0.000 description 7
- 239000007759 RPMI Media 1640 Substances 0.000 description 6
- 206010003757 Atypical pneumonia Diseases 0.000 description 5
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000038129 antigens Human genes 0.000 description 4
- 108091007172 antigens Proteins 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 210000003462 Veins Anatomy 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000241 respiratory Effects 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 102000011931 Nucleoproteins Human genes 0.000 description 2
- 108010061100 Nucleoproteins Proteins 0.000 description 2
- 101710033747 S6 Proteins 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M Caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000033180 ERVK-6 Human genes 0.000 description 1
- 101710038044 ERVK-6 Proteins 0.000 description 1
- 101710027967 ERVW-1 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 101700032567 GATM Proteins 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- 101710023234 Segment 5 Proteins 0.000 description 1
- 101700028070 VPX Proteins 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940098124 cesium chloride Drugs 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410044285 CN1276777C (en) | 2003-05-21 | 2004-05-18 | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03126634.7 | 2003-05-21 | ||
CN03126634 | 2003-05-21 | ||
CN 200410044285 CN1276777C (en) | 2003-05-21 | 2004-05-18 | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1562365A CN1562365A (en) | 2005-01-12 |
CN1276777C true CN1276777C (en) | 2006-09-27 |
Family
ID=34523618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410044285 Expired - Fee Related CN1276777C (en) | 2003-05-21 | 2004-05-18 | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1276777C (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100479858C (en) * | 2005-01-27 | 2009-04-22 | 中国医学科学院实验动物研究所 | A recombined smallpox vaccine - SARS vaccine and preparation method thereof |
WO2006079290A1 (en) * | 2005-01-27 | 2006-08-03 | Institute Of Laboratory Animal Science Of Chinese Academy Of Medical Sciences | A recombinant sars-cov vaccine comprising attenuated vaccinia virus carriers |
CN101020055B (en) * | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | SARS vaccine based on replicative vaccinia virus vector |
CN102844663B (en) * | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | Based on the immunogenic formulation of cytomegalovirus |
CN111317816A (en) * | 2020-02-05 | 2020-06-23 | 翁炳焕 | Preparation method of novel coronavirus pneumonia bivalent vaccine |
CN113248577B (en) * | 2020-02-12 | 2022-10-21 | 北京科兴中维生物技术有限公司 | Coronavirus vaccine using adenovirus as carrier and its preparing method |
CN111228475A (en) * | 2020-02-21 | 2020-06-05 | 赛诺(深圳)生物医药研究有限公司 | Biological product for preventing novel coronavirus |
US20220347289A1 (en) * | 2020-02-23 | 2022-11-03 | Guangzhou N Biomed Ltd. | Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof |
EP3922263A4 (en) * | 2020-03-16 | 2022-06-29 | Guangzhou N Biomed Ltd. | Ad7 vector vaccine for preventing sars-cov-2 infection |
EP3912638A4 (en) * | 2020-03-16 | 2022-07-13 | Guangzhou N Biomed Ltd. | Ad35 vector vaccine for preventing sars-cov-2 infection |
CN112206318B (en) * | 2020-03-16 | 2021-08-03 | 广州恩宝生物医药科技有限公司 | Ad7 vector vaccine for preventing SARS-CoV-2 infection |
WO2021207962A1 (en) * | 2020-04-15 | 2021-10-21 | Active Motif Shanghai Limited | Antibodies to sars-coronavirus (covid-19) s1 spike protein |
CN113750227A (en) * | 2020-06-01 | 2021-12-07 | 康希诺生物股份公司 | SARS-CoV-2 vaccine |
CN112641937A (en) * | 2020-10-15 | 2021-04-13 | 广州达博生物制品有限公司 | Application of recombinant adenovirus in preparing medicine for preventing virus |
CN112618707A (en) * | 2020-10-15 | 2021-04-09 | 广州达博生物制品有限公司 | SARS-CoV-2 coronavirus vaccine and its preparation method |
CN114164220B (en) * | 2022-01-13 | 2022-08-12 | 广州达博生物制品有限公司 | Nucleotide sequence for constructing novel coronavirus vaccine and application thereof |
CN114807179B (en) * | 2022-06-01 | 2022-10-21 | 广州达博生物制品有限公司 | Construction and application of novel coronavirus pneumonia vaccine |
-
2004
- 2004-05-18 CN CN 200410044285 patent/CN1276777C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1562365A (en) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1276777C (en) | SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene | |
Feng et al. | Canine parvovirus VP2 protein expressed in silkworm pupae self-assembles into virus-like particles with high immunogenicity | |
CN1925870A (en) | DNA vaccine expressing HA1 of equine-2 influenza virus | |
CN1275084A (en) | Recombinant porcine adenovirus vector | |
CN1903363A (en) | Mosaic type virus-like particle DNA vaccine | |
Tan et al. | Infectious bronchitis virus poly-epitope-based vaccine protects chickens from acute infection | |
Jia et al. | Protective immunity of largemouth bass immunized with immersed DNA vaccine against largemouth bass ulcerative syndrome virus | |
CN1730101A (en) | O type foot-and-mouth disease virus poly-gene duplication defect type adenovirus active carrier vaccine and preparation method | |
CN1718242A (en) | The canine adenovirus type 2 recombiant vaccine of rabies virus sugar/structural protein such as nuclear | |
CN1858062A (en) | Enzyme-linked immunosorbent test detecting reagent kit for non-structure protein of pig and cow foot and mouth disease virus | |
Abid et al. | Generation and immunogenicity of a recombinant pseudorabies virus co-expressing classical swine fever virus E2 protein and porcine circovirus type 2 capsid protein based on fosmid library platform | |
CN1933852A (en) | Improved inactivated FCV vaccines | |
CN1763085A (en) | Avian infectious brunchitis virus s1 recombinant protein antigen, preparation method and uses | |
CN114164220B (en) | Nucleotide sequence for constructing novel coronavirus vaccine and application thereof | |
CN1276778C (en) | SARS nucleic acid vaccine and preparation method, application of S gene in coronavirus | |
CN100335636C (en) | Thioredoxin gene of Schistosoma japonicum (Chinese Mainland Strain) and its cloning expression method and application | |
CN1943789A (en) | The DNA vaccine of an anti-infection of hepatitis C virus | |
CN1778812A (en) | Nolvac viral coat protein with recombinant rod virus expression and its preparation | |
CN1761745A (en) | A novel human virus causing severe acute respiratory syndrome (SARS) and uses thereof | |
CN1273482C (en) | Hepatitis C virus tunic protein E2 gene capable of being total length expressed in E. coli, its coding protein and use | |
CN1239512A (en) | Replication-competent recombinant sabin type 1 strain of pollovirus | |
CN1522760A (en) | Bivalent gene engineering vaccine of fowl infectious bursal disease and pasteurellosis | |
CN1663616A (en) | Rotavirus gene vaccine based on NSP4 gene | |
WO2013030608A1 (en) | Nanoparticle-based veterinary vaccine | |
CN1778926A (en) | Modified pig propagation and respiratory syndrome virus ORF5 gene and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Shenzhen City Sibiono Gene Technology Co., Ltd. Assignor: Tumor Prevention and Therapy Center, Zhongshan Univ Contract fulfillment period: 2007.4.25 to 2024.5.17 contract change Contract record no.: 2008440000382 Denomination of invention: SARS vaccine of adenovirus carrier and preparation method, application of coronavirus S gene Granted publication date: 20060927 License type: Exclusive license Record date: 20081117 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.4.25 TO 2024.5.17; CHANGE OF CONTRACT Name of requester: SHENZHEN CITY SAIBAINUO GENE TECHNOLOGY CO., LTD. Effective date: 20081117 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060927 Termination date: 20170518 |